BPG is committed to discovery and dissemination of knowledge
Cited by in CrossRef
For: Bohra A, Rizvi QAA, Keung CYY, Vasudevan A, van Langenberg DR. Transitioning patients with inflammatory bowel disease from hospital-based to rapid home-based infliximab: A stepwise, safety and patient-orientated process towards sustainability. World J Gastroenterol 2020; 26(36): 5437-5449 [PMID: 33024395 DOI: 10.3748/wjg.v26.i36.5437]
URL: https://www.wjgnet.com/1007-9327/full/v26/i36/5437.htm
Number Citing Articles
1
Virginia Solitano, Ludovico Alfarone, Ferdinando D’Amico, Laurent Peyrin-Biroulet, Silvio Danese. IBD goes home: from telemedicine to self-administered advanced therapiesExpert Opinion on Biological Therapy 2022; 22(1): 17 doi: 10.1080/14712598.2021.1942833
2
Janson Jacob, Daniel Aintabi, Melissa DeJonckheere, Shirley A. Cohen-Mekelburg, John I. Allen, David N. Irani, A. Mark Fendrick, Akbar K. Waljee, Peter D.R. Higgins, Jeffrey A. Berinstein. Inflammatory bowel disease patient concerns and experiences on transition to home-based infusions during the COVID-19 pandemicResearch in Social and Administrative Pharmacy 2022; 18(12): 4138 doi: 10.1016/j.sapharm.2022.06.009
3
InfliximabReactions Weekly 2021; 1841(1): 131 doi: 10.1007/s40278-021-90633-x
4
Timothy J. Schultz, Anne Thomas, Paul Georgiou, Mahasen S. Juaton, Lynette Cusack, Lorraine Simon, Kerisha Naidoo, Kevin Webb, Jonathan Karnon, Janakan Ravindran. Home infusions of natalizumab for people with multiple sclerosis: a pilot randomised crossover trialAnnals of Clinical and Translational Neurology 2021; 8(8): 1610 doi: 10.1002/acn3.51410
5
Beate Bittner. Customer-centric product presentations for monoclonal antibodiesAAPS Open 2023; 9(1) doi: 10.1186/s41120-022-00069-y